Absci Collaborates With Memorial Sloan Kettering Cancer Center To Discover Novel Therapeutics Using Generative AI
Portfolio Pulse from Benzinga Newsdesk
Absci Corporation (NASDAQ:ABSI) has announced a collaboration with Memorial Sloan Kettering Cancer Center to discover and develop novel therapeutics using generative AI. The partnership will focus on up to six programs, leveraging Absci's Integrated Drug Creation™ platform.
August 12, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci Corporation has entered into a collaboration with Memorial Sloan Kettering Cancer Center to develop novel therapeutics using generative AI. This partnership could enhance Absci's reputation and capabilities in AI-driven drug discovery.
The collaboration with a prestigious institution like Memorial Sloan Kettering Cancer Center is likely to boost investor confidence in Absci's capabilities and future prospects. The use of generative AI in drug discovery is a cutting-edge approach that could lead to significant advancements and market opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100